COMP360 Just Cleared Its Second Phase 3 Trial. Here's Why That Changes Everything.

February 28, 2026

Thursday morning I was three espressos deep in my Leipzig apartment, refreshing the Compass Pathways investor page like a lunatic, when the press release loaded. COMP360 hit its second Phase 3 endpoint. I knocked my coffee over. My cat bolted. I called Petra at Charité and said two words: It hit.

That was February 20th.

No classic psychedelic has ever achieved two positive Phase 3 readouts before. Not psilocybin, not MDMA, not LSD, not DMT, not anything that agonizes a serotonin 2A receptor. This is a first. Full stop.

And the data is worth sitting with.

The Numbers from COMP006

Compass tested two doses of synthetic psilocybin against an active comparator — meaning the control group also got a small dose. They learned from the Lykos disaster in 2024 where MDMA patients could obviously tell they were tripping versus placebo and the whole blinding fell apart. So Compass used micro-dose psilocybin as control. Everyone has some experience. Nobody can game the blind. Clever.

25 mg dose. Week six. 39 percent of treatment-resistant patients showed at least 25 percent improvement on the MADRS depression scale. Effects persisted over 26 weeks with one or two doses.

You need context for why 39 percent matters. Treatment-resistant means these people already tried SSRIs, SNRIs, probably therapy, maybe ECT. Failed everything. The standard response rate when you try yet another antidepressant on this population is maybe 20 to 25 percent, requires daily pills, and comes packaged with weight gain and killed libido and emotional numbness that patients describe as watching life through a window.

One psilocybin session. Better numbers. Half a year of improvement. No daily pill.

A mushroom compound just embarrassed the entire antidepressant aisle at CVS in the hardest patients. I laugh about this and then I get angry that we criminalized it for fifty years.

Washington Is Being Washington

Compass plans to file their NDA between October and December this year. Best case: launch in 2027. First classic psychedelic ever approved in America.

But the politics are absurd.

RFK Jr. tells Congress psychedelics have "tremendous advantage" in clinical settings. Marty Makary at FDA promises speedy review. Then in October somebody at HHS quietly removes COMP360 from the National Priority Voucher list — a fast-track that would have cut months off review time. STAT News broke this February 4th. No explanation.

Kennedy waving pom-poms. Unnamed bureaucrat pulling the brake. Classic.

And while this soap opera plays out, the DEA just bumped its 2026 psilocybin production quota by 67 percent because research demand outstripped supply. The drug warriors are now the logistics team for clinical psilocybin research. I genuinely cannot make this stuff up.

Money Follows Data

AbbVie paid $1.2 billion for bretisilocin from Gilgamesh Pharmaceuticals. AbbVie. The Humira company. $300-billion market cap. Their analysts do not write billion-dollar checks on vibes. Five companies are now in late-stage psychedelic trials: Compass, Helus Pharma (was Cybin, rebranded January, now trades as HELP), Relmada, Alto Neuroscience, Axsome. Institutional money, real balance sheets. The venture-capital-and-dreams era is done.

Not Just Depression Anymore

Dr. Terence Ching at Yale wrapped his second psilocybin-for-OCD trial this month. First study used 0.25 mg/kg body weight, showed clear efficacy. Second study tested double dosing. OCD is brutal — 40 to 60 percent of patients fail first-line SSRIs and finding a trained ERP therapist is nearly impossible outside major cities.

And luvesilocin. Never heard of it until this week? Reunion Neuroscience just got Breakthrough Therapy designation from FDA for this psilocybin analog targeting postpartum depression. Phase 3 planned for 2026. Current PPD treatment involves a 60-hour IV drip that costs $34,000. A supervised oral session could blow that model apart.

The World Is Ahead of Us

Australia: legal psilocybin prescriptions since July 2023. Germany: first EU compassionate-use program, centers in Mannheim and Berlin. Czech Republic: medical psilocybin legal since January 1. The BMJ published a comprehensive psychedelic medicine review on February 23rd. When a journal that has been running since 1840 says this is real, the holdouts start listening.

Why You Should Care Even If You Just Take Lion's Mane

Psilocybin's mechanism — 5-HT2A agonism triggering BDNF release and dendritic spine growth — is a neuroplasticity mechanism. It rewires stuck neural circuits. SSRIs just keep serotonin floating in the synapse longer. Totally different thing.

Lion's mane does something parallel through NGF and erinacines. Different molecular door, same house. If you are taking lion's mane daily you are supporting the same fundamental brain remodeling process that makes psilocybin work clinically. Lower intensity, different pathway, totally legal.

For stacking strategies that use these complementary pathways, our mushroom stacks guide covers the logic.

Dr. Igor's Take

I told my PhD advisor in 2021 psilocybin would clear Phase 3 within five years. He laughed. I should call him.

The data held. Two trials. It held.

My worry now: Kennedy muscling this through makes it look political instead of scientific. The backlash will come either way — anything threatening the SSRI paradigm always draws fire — but let the data lead, not a politician.

One more thing keeping me awake. Helus Pharma published SPL026 Phase 2a data in Nature Medicine this month. 34 patients, three UK sites, single 21.5 mg dose. MADRS reduction: -7.35 versus placebo, p-value 0.023. Their compound HLP003 showed 100 percent response and 71 percent remission at twelve months from two doses. Two doses. If Phase 3 confirms, we are looking at not one psychedelic drug but an entire new class.

The fungi are winning. I need more coffee.

Check our complete 2026 functional mushrooms guide for the big picture. And if your supplement label says "mycelium on grain" instead of "fruiting body," our breakdown explains why you might be paying for expensive oats.

FAQ